Updated View On Ocera Therapeutics (NASDAQ: OCRX) After Phase 2 STOP-HE Trial

OCRX

Ocera Therapeutics (OCRX) announced yesterday that the phase 2 study of OCR-002, an ammonia scavenger, failed to reach statistical significance at the primary end-point. We listened to the management's conference call. The study showed that the severity of acute hepatic encephalopathy ((HE)) corr...

Ocera Therapeutics (OCRX) announced yesterday that the phase 2 study of OCR-002, an ammonia scavenger, failed to reach statistical significance at the primary end-point. We listened to the management's conference call. The study showed that the severity of acute hepatic encephalopathy ((HE)) corr...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics